Biofil Chemicals Peer Comparison

NSE: BIOFILCHEM | BSE: 524396

₹31.97

₹0.02 (0.06%)

As on 03-Sep-2026 15:59IST

Market cap

₹52 Cr

Revenue (TTM)

₹34 Cr

P/E Ratio

107

P/B Ratio

2.4

Div. Yield

0 %

Edit

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	52	31,767	29,293	28,544	26,191
Revenue (₹ Cr)	34	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	0.48	414.00	288.22	-371.81	387.35
Net Margin (%)	1.39	11.23	14.79	-3.93	26.01
RoE (%)	2.25	8.38	29.77	-3.85	25.18
Price to Earnings	107.03	77.67	101.64	--	67.81
Price-To-Book	2.38	6.31	21.82	3.57	15.18

Income Statement (₹ Cr)

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	34.31	3,564.00	1,935.80	9,205.28	1,461.80
Total Income	34.63	3,686.00	1,948.58	9,449.59	1,489.25
Total Expenditure	33.53	2,792.00	1,485.56	8,195.15	919.25
EBITDA	0.78	772.00	450.24	1,010.13	542.56
Depreciation	0.27	226.00	50.83	857.51	37.68
EBIT	0.51	546.00	399.41	152.62	504.88
Interest	0.00	217.00	40.84	342.73	3.77
Other Income	0.31	122.00	12.78	244.31	27.45
Exceptional Items	0.00	12.00	0.00	-216.88	0.00
Profit before Tax	0.82	463.00	371.35	-162.68	528.56
Provision for Tax	0.34	49.00	83.14	209.13	141.21
Profit after Tax	0.48	414.00	288.22	-371.81	387.35

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	21.56	4,940.00	1,288.82	8,162.62	1,653.56
Minority Interest	0.00	-5.00	0.00	0.00	-1.13
Non-Current Liabilities	0.60	1,712.00	202.03	5,044.14	42.40
Current Liabilities	20.69	1,622.00	835.87	4,758.28	230.82
Total Liabilities	42.85	8,578.00	2,326.71	17,723.32	1,983.96

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	6.94	5,343.00	519.60	10,211.52	1,026.85
Current Assets	35.86	2,606.00	1,681.81	7,191.66	881.27
Total Assets	42.85	8,578.00	2,326.71	17,723.32	1,983.96
Total Debt*	3.02	2,125.00	259.37	5,495.48	26.49
Net Current Assets	15.17	984.00	845.94	2,433.38	650.46
Contingent Liabilities	--	768.26	19.09	95.72	17.25

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	-0.60	390.00	205.05	1,652.60	292.17
Cash Flow from Investing Activities	1.14	-241.00	-409.72	-826.03	-265.94
Cash from Financing Activities	2.54	-54.00	283.07	-38.98	4.10
Net Cash Inflow / Outflow	3.07	95.00	78.39	787.59	30.33

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	15.78	6.79	29.22	1.24	32.42
ROE (%)	2.25	8.38	29.77	-3.85	25.18
ROA (%)	1.03	4.94	24.77	-2.21	21.93
EBIT Margin (%)	1.49	15.32	20.63	1.66	34.54
Net Margin (%)	1.39	11.23	14.79	-3.93	26.01
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	9.30	18.37	46.65	0.78	40.90
EBIT Growth (%)	156.28	252.26	62.13	-70.53	124.50
Net Profit Growth (%)	-82.79	377.85	89.49	-1,383.43	104.15
EPS Growth (%)	-82.79	1,001.33	78.60	-484.84	42.32
Book Value Growth (%)	14.82	13.47	144.31	0.33	26.03

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	107.54	79.48	100.48	-91.37	67.83
Price / Book Value	2.39	6.29	21.91	3.57	15.18
Dividend Yield (%)	0.00	0.00	0.08	0.00	0.08
EV/EBITDA	65.72	42.92	65.13	32.40	47.92
Market Cap (₹ Cr)	42.12	19,071.62	12,753.19	18,108.89	20,944.75

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.00	0.31	0.11	0.53	0.02
Short term debt to equity ratio	0.14	0.09	0.05	0.09	0.02
Current Ratio	1.73	1.61	2.01	1.51	3.82
Quick Ratio	1.54	1.06	1.14	0.87	2.82
Interest Coverage	411.00	3.13	10.09	0.53	141.16

	Biofil Chemicals	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	80.40	16.50	26.28	23.44	24.80
Asset Turnover	0.73	0.43	1.66	0.55	0.83
Receivable days	423.56	58.75	40.13	78.20	88.98
Inventory Days	47.18	75.82	60.29	93.30	56.04
Payable days	337.77	186.21	232.47	226.14	99.95
Cash Conversion Cycle	132.97	-51.64	-132.04	-54.64	45.07

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.